MG-K10 Phase III Trial, Adolescents, Moderate-to-Severe Atopic Dermatitis
Summary
NIH registered a Phase III clinical trial (NCT07540442) for MG-K10, a humanized monoclonal antibody injection, in adolescents with moderate-to-severe atopic dermatitis. The randomized, double-blind, placebo-controlled, parallel-group study aims to confirm the efficacy and safety of MG-K10 monotherapy. Trial conditions are limited to atopic dermatitis; no other indications are listed.
What changed
NIH registered a new Phase III clinical trial (NCT07540442) for MG-K10, a humanized monoclonal antibody injection, as monotherapy for adolescents aged 12+ with moderate-to-severe atopic dermatitis. The study is a randomized, double-blind, placebo-controlled parallel-group trial designed to confirm efficacy and safety. Trial arms include MG-K10 Injection and placebo.\n\nSponsors and clinical investigators monitoring ongoing or competing atopic dermatitis programs should note this trial as a competitive development milestone in the adolescent AD indication space. The trial does not impose external compliance obligations on other parties.
Archived snapshot
Apr 20, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis
Phase 3 NCT07540442 Kind: PHASE3 Apr 20, 2026
Abstract
This is a randomized, double-blind, placebo-controlled, parallel group study to confirm the efficacy and safety of MG-K10 monotherapy in adolescents with moderate-to-severe atopic dermatitis (AD)
Conditions: Dermatitis, Atopic
Interventions: MG-K10 Injection (Humanized Monoclonal Antibody), Placebo for MG-K10
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.